End-of-day quote
Shanghai S.E.
18:00:00 2024-06-27 EDT
|
5-day change
|
1st Jan Change
|
28.94
CNY
|
-1.53%
|
|
-11.15%
|
-11.47%
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
5,774
|
13,063
|
11,564
|
-
|
-
|
Enterprise Value (EV)
1 |
5,774
|
13,063
|
11,564
|
11,564
|
11,564
|
P/E ratio
|
-5.92
x
|
-12.4
x
|
-12.6
x
|
-18
x
|
-87.7
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
102
x
|
34.5
x
|
11.7
x
|
6.26
x
|
EV / Revenue
|
-
|
102
x
|
34.5
x
|
11.7
x
|
6.26
x
|
EV / EBITDA
|
-
|
-13.4
x
|
-14.4
x
|
-23.7
x
|
336
x
|
EV / FCF
|
-
|
-10.2
x
|
-13.4
x
|
-18.4
x
|
1,296
x
|
FCF Yield
|
-
|
-9.82%
|
-7.44%
|
-5.43%
|
0.08%
|
Price to Book
|
-
|
5.05
x
|
6.95
x
|
11.3
x
|
13
x
|
Nbr of stocks (in thousands)
|
399,600
|
399,600
|
399,600
|
-
|
-
|
Reference price
2 |
14.45
|
32.69
|
28.94
|
28.94
|
28.94
|
Announcement Date
|
2/20/23
|
2/23/24
|
-
|
-
|
-
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
127.7
|
334.7
|
991.7
|
1,847
|
EBITDA
1 |
-
|
-973
|
-804.6
|
-487.7
|
34.43
|
EBIT
1 |
-
|
-1,053
|
-940.3
|
-667.4
|
-156.7
|
Operating Margin
|
-
|
-824.53%
|
-280.92%
|
-67.3%
|
-8.48%
|
Earnings before Tax (EBT)
1 |
-
|
-1,056
|
-921
|
-642.4
|
-131.7
|
Net income
1 |
-954
|
-1,053
|
-919
|
-640.8
|
-131.4
|
Net margin
|
-
|
-824.94%
|
-274.55%
|
-64.62%
|
-7.11%
|
EPS
2 |
-2.440
|
-2.640
|
-2.298
|
-1.604
|
-0.3300
|
Free Cash Flow
1 |
-
|
-1,283
|
-860.8
|
-627.7
|
8.925
|
FCF margin
|
-
|
-1,004.52%
|
-257.16%
|
-63.29%
|
0.48%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
25.92%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/20/23
|
2/23/24
|
-
|
-
|
-
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-1,283
|
-861
|
-628
|
8.93
|
ROE (net income / shareholders' equity)
|
-
|
-34.5%
|
-55.8%
|
-58.7%
|
-15%
|
ROA (Net income/ Total Assets)
|
-
|
-23.6%
|
-27.5%
|
-19.1%
|
-4.1%
|
Assets
1 |
-
|
4,464
|
3,348
|
3,364
|
3,205
|
Book Value Per Share
2 |
-
|
6.470
|
4.160
|
2.560
|
2.230
|
Cash Flow per Share
2 |
-
|
-1.960
|
-2.980
|
-0.9200
|
0.0200
|
Capex
1 |
-
|
500
|
120
|
95.1
|
55.1
|
Capex / Sales
|
-
|
391.51%
|
35.88%
|
9.59%
|
2.98%
|
Announcement Date
|
2/20/23
|
2/23/24
|
-
|
-
|
-
|
Last Close Price
28.94
CNY Average target price
48
CNY Spread / Average Target +65.86% Consensus |
1st Jan change
|
Capi.
|
---|
| -11.47% | 1.59B | | +15.20% | 121B | | +19.67% | 113B | | +18.95% | 26.02B | | -23.86% | 19.39B | | -19.03% | 15.91B | | -20.90% | 15.09B | | -46.14% | 15.06B | | +63.85% | 14.93B | | +4.49% | 13.85B |
Bio Therapeutic Drugs
|